相关实验视频

Updated: Jan 11, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

缺少PTEN会损害依赖IL-15的T细胞免疫力,抵抗前列腺癌

Yujie Xing¹, Zixuan Zeng¹, Chi Wang¹

¹Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Biochemical and biophysical research communications

|November 18, 2025

概括

前列腺癌中的酸酶和张素同类素 (PTEN) 损失通过抑制IL-15减少T细胞透,从而减少T细胞透. 恢复IL-15可以增强抗瘤免疫力,这表明IL-15治疗PTEN缺陷前列腺癌.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

前列腺癌 (PCa) 往往是免疫学上"冷",由于免疫细胞透不良,限制了免疫治疗的有效性.
酸酶和张素同类素 (PTEN) 的损失是PCa发展和进展的关键驱动因素.
PTEN缺乏对瘤免疫微环境,特别是T细胞活性的影响尚不清楚.

研究的目的:

研究PTEN缺乏如何影响前列腺癌中T细胞透和抗瘤免疫力.
阐明将PTEN损失与PCa.中的免疫逃避联系起来的分子机制.
探索IL-15在PTEN缺乏PCa中的治疗潜力.

主要方法:

对PTEN缺乏和T细胞透在人类PCa组织中的分析.
在小鼠同源性瘤模型中,CRISPR/Cas9介导的Pten淘汰.
评估IL-15的产生和cGAS-STING通路的激活.
评估IL-15恢复对T细胞透和抗瘤免疫的影响.

主要成果:

PTEN缺乏与人类PCa中T细胞透率降低相关.
在小鼠模型中,Pten淘汰会导致内CD8+T细胞积累的减少.
通过受损的cGAS-STING信号传递,PTEN损失抑制了IL-15的产生.
在缺乏Pten的PCa细胞中恢复IL-15可增强T细胞透和抗瘤反应.

结论:

在前列腺癌中,PTEN是IL-15介导的T细胞免疫的关键调节者.
由于抑制IL-15的产生,PTEN缺乏会损害抗瘤免疫力.
基于IL-15的疗法在治疗PTEN缺陷前列腺癌方面表现有前途.

关键词:

在IL-15中,IL-15是最常见的.免疫微环境是一个微环境.在这里,我们可以使用PTEN.前列腺癌是什么意思前列腺癌是什么意思

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.